Loading data for ABVC — first visit, this takes a few seconds.
ABVC BioPharma Inc. (ABVC)
NasdaqCM: ABVC
· Real-Time Price · USD
0.93
+0.06 (6.90%)
At close: Aug 19, 2026, 4:43 PM
ABVC BioPharma Inc. (ABVC) Stock Price, Analysis & Data
6.90% (1D)
No data available
| Bid | n/a |
| Market Cap | 24.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.63M |
| Beta | 0.63 |
| EPS (ttm) | -0.29 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.12 |
| P/B (ttm) | 2.04 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 63,522 |
| Avg. Volume (20D) | 146,508 |
| Open | 0.93 |
| Previous Close | 0.87 |
| Day's Range | 0.89 - 0.95 |
| 52-Week Range | 0.82 - 3.40 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ABVC
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperac...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 10, 2004
Employees 16
Stock Exchange NasdaqCM
Ticker Symbol ABVC
Website https://www.abvcpharma.com
Financial Performance
In 2025, ABVC BioPharma's revenue was 0, a decrease of -100% compared to the previous year's 509.59K. Earnings were -7.91M, an increase of 61.3%.
Financial StatementsEarnings Surprise
ABVC BioPharma has released their quarterly earnings on May 15, 2023:
